Regulated Necrosis Hypothesis in Parkinson's Disease

📖 Wiki Page

hypothesis3098 wordssynced 2026-04-02

Regulated Necrosis Hypothesis in Parkinson's Disease

Overview

The Regulated Necrosis Hypothesis proposes that multiple distinct forms of programmed necrosis—specifically necroptosis, parthanatos, and autosis—converge to drive progressive dopaminergic neurodegeneration in Parkinson's Disease (PD). Unlike classical apoptosis, regulated necrosis pathways are characterized by inflammatory cell death that releases damage-associated molecular patterns (DAMPs), creates a neurotoxic microenvironment, and amplifies the very processes that initiate neuronal death[@dang2021]. The convergence of these pathways provides a unified mechanistic explanation for the inflammatory milieu observed in PD brains and suggests combinatorial therapeutic strategies targeting multiple necrosis pathways simultaneously.

Mechanistic Model

Core Convergence Framework

```mermaid
flowchart TD
subgraph Upstream_Triggers
A["alpha-Syn Oligomers"] --> D["Neuroinflammation (TNF-alpha, IL-1beta)"]
B["Mitochondrial Dysfunction"] --> D
C["DNA Damage"] --> D
E["Oxidative Stress (ROS)"] --> D
end

subgraph Necroptosis_Path
D --> F["TNFR1 Activation"]
F --> G["RIPK1 Activation"]
G --> H["RIPK3 Recruitment"]
H --> I["MLKL Phosphorylation"]
I --> J["Membrane Pore Formation"]
J --> K["Cell Lysis DAMP Release"]
end

...

Regulated Necrosis Hypothesis in Parkinson's Disease

Overview

Mechanistic Model

Core Convergence Framework

Mermaid diagram (expand to render)

1. Necroptosis Pathway

Necroptosis is a TNF-α-dependent programmed necrosis pathway mediated by the receptor-interacting protein kinases [RIPK1](/entities/ripk1) and [RIPK3](/entities/ripk3) and the pseudokinase [MLKL](/entities/mlkl-protein). In PD, several upstream triggers activate this pathway[@bhatt2024][@chen2023]:

TNF-α elevation: Post-mortem PD brains show elevated [TNF-α](/entities/tnf-alpha) in the substantia nigra and CSF, driven by chronic neuroinflammation
Alpha-synuclein toxicity: Oligomeric [alpha-synuclein](/entities/alpha-synuclein) can activate RIPK1 through pattern recognition receptors, initiating necroptosis signaling
Mitochondrial dysfunction: Loss of mitochondrial membrane potential can sensitize cells to necroptotic death

The necroptotic cascade proceeds as follows:

[TNF-α](/entities/tnf-alpha) binds [TNFR1](/entities/tnfr1-protein), recruiting TRADD and [RIPK1](/entities/ripk1)

In the presence of [caspase-8](/entities/caspase-8) inhibition (common in stressed neurons), RIPK1 recruits [RIPK3](/entities/ripk3)

RIPK3 phosphorylates [MLKL](/entities/mlkl-protein), causing MLKL trimerization and plasma membrane pore formation

Cell contents leak, releasing HMGB1, ATP, and other DAMPs that propagate inflammation[@wang2024]

2. Parthanatos Pathway

Parthanatos is a caspase-independent cell death pathway initiated by poly(ADP-ribose) polymerase-1 ([PARP1](/entities/parp1)) hyperactivation. In PD, DNA damage is a well-documented finding[@mandir2009][@yu2022]:

Oxidative DNA damage: Increased 8-OHdG in PD brains and CSF
Mitochondrial DNA damage: Accumulation of mtDNA mutations in dopaminergic neurons
Environmental toxin exposure: [MPTP](/entities/mptp), rotenone, and paraquat cause DNA alkylation

The parthanatos cascade:

Extensive DNA damage activates [PARP1](/entities/parp1), consuming NAD⁺ and ATP

PAR polymer accumulation signals for mitochondrial release of apoptosis-inducing factor ([AIF](/entities/aifm1-protein))

AIF translocates to the nucleus, causing large-scale DNA fragmentation (50+ kb fragments)

Energy depletion leads to cell death without caspase activation

PARP inhibitors (e.g., veliparib, rucaparib) have shown neuroprotection in PD models[@liu2020], though clinical translation has been limited by the need for brain-penetrant compounds.

3. Autosis Pathway

Autosis is a Na⁺/K⁺-ATPase-dependent autophagic cell death form with unique features[@kandel2021][@zhang2022]:

Na⁺/K⁺-ATPase dysfunction: Implicated in both familial and sporadic PD; ouabain-sensitive pump failure leads to lethal autophagy
Cathepsin involvement: [Cathepsin B](/entities/cathepsin-b) and [Cathepsin L](/entities/cathepsin-l) mediate the final execution steps
Atg5-independent autophagy: Distinguishes autosis from conventional autophagic cell death

4. Convergence Points

The three pathways are not independent—they share critical convergence nodes:

| Node | Necroptosis | Parthanatos | Autosis |
|------|-------------|-------------|---------|
| Energy crisis | ATP depletion accelerates | Direct NAD⁺/ATP consumption | Requires functional ATP |
| Oxidative stress | ROS amplifies necroptosis | ROS causes DNA damage | ROS triggers autophagy |
| Inflammation | DAMP release | PAR release triggers inflammation | Cathepsin release |
| Mitochondrial dysfunction | Permissive for activation | Direct AIF release | Energy failure |

Integration with Existing Mechanisms

Mermaid diagram (expand to render)

Evidence Assessment

Confidence Level: Moderate-Strong

The regulated necrosis hypothesis has substantial supporting evidence across multiple pathways.

| Evidence Type | Level | Supporting Data |
|---------------|-------|-----------------|
| Post-mortem | Strong | Elevated TNF-α, RIPK1, phospho-MLKL in PD SN |
| Biomarkers | Moderate | PAR polymers in PD CSF, reduced Na⁺/K⁺-ATPase |
| Preclinical models | Strong | RIPK1, PARP inhibitors protect in MPTP/6-OHDA |
| Genetic | Moderate | GWAS hits in necrosis pathway genes |
| Therapeutic Translation | Moderate | Multiple drug candidates in pipeline |

Key Supporting Studies

Bhatt et al. (2024) — Comprehensive review establishing necroptosis as driver of neurodegeneration in PD models[@bhatt2024]

Chen et al. (2023) — Direct demonstration of RIPK3-MLKL pathway activation in PD patient dopaminergic neurons[@chen2023]

Mandir et al. (2009) — Found that PARP-mediated cell death is essential for MPTP-induced neurodegeneration[@mandir2009]

Kandel et al. (2021) — Characterized autosis in PD models, showing Na⁺/K⁺-ATPase inhibition as therapeutic target[@kandel2021]

Wang et al. (2024) — RIPK1 inhibitors show efficacy in multiple preclinical PD models[@wang2024]

Key Challenges and Contradictions

Pathway specificity: Distinguishing necroptosis from other cell death forms in vivo is challenging
Biomarker development: Reliable human biomarkers for pathway activation are lacking
Combination therapy: Single pathway inhibition may be insufficient given convergence

Testability Score: 8/10

Model systems: MPTP, 6-OHDA, α-synuclein models available
Biomarkers: PAR levels, phospho-MLKL, cathepsin activity measurable
Inhibitors: Multiple drug candidates available
Challenge: Human pathway activation difficult to assess post-mortem

Therapeutic Potential Score: 9/10

The regulated necrosis pathways offer multiple therapeutic targets:

RIPK1 inhibitors: Already in clinical trials for other indications
PARP inhibitors: FDA-approved for oncology, brain-penetrant variants in development
Na⁺/K⁺-ATPase modulators: Existing cardiac glycosides with potential repurposing

Key Proteins and Genes

| Protein/Gene | Role in Pathway | Relevance to PD |
|--------------|-----------------|-----------------|
| [RIPK1](/entities/ripk1) | Kinase, necroptosis initiator | Elevated in PD substantia nigra |
| [RIPK3](/entities/ripk3) | Kinase, necroptosis executor | Phosphorylated in PD neurons |
| [MLKL](/entities/mlkl-protein) | Pseudokinase, membrane pore | Activated in PD brain |
| [PARP1](/entities/parp1) | DNA repair, cell death | Hyperactivated in PD |
| [AIFM1](/entities/aifm1-protein) | Mitochondrial cell death | Translocates to nucleus in PD |
| [ATP1A3](/entities/atp1a3-protein) | Na⁺/K⁺-ATPase α3 subunit | Mutations cause rapid-onset dystonia-PD |
| [CATB](/entities/cathepsin-b) | Lysosomal protease | Elevated in PD brain |
| [CATL](/entities/cathepsin-l) | Lysosomal protease | Involved in autosis |
| [TNF-α](/entities/tnf-alpha) | Pro-inflammatory cytokine | Elevated in PD CSF |
| [TNFR1](/entities/tnfr1-protein) | TNF receptor | Initiates necroptosis |
| [TFAM](/entities/tfam-protein) | Mitochondrial transcription | Declines in PD SN |
| [SQSTM1](/entities/sqstm1-protein) | Autophagy receptor | Accumulated in Lewy bodies |

Disease Progression Model

Mermaid diagram (expand to render)

| Stage | Necroptosis Markers | Parthanatos Markers | Autosis Markers |
|-------|---------------------|---------------------|----------------|
| Preclinical | p-RIPK1± | p-PARP1± | Na+/K+-ATPase down |
| Early PD | p-RIPK1+ | PAR+ | Activity down |
| Established PD | p-RIPK3+, p-MLKL+ | p-PARP1++ | Pump failure |
| Advanced PD | MLKL membrane+ | AIF nuclear+ | Cathepsin release |

Biomarker Development

Diagnostic Biomarkers

| Biomarker | Source | Pathway | Utility |
|----------|--------|---------|----------|
| Phospho-MLKL | CSF, plasma | Necroptosis | Early detection |
| PAR polymer | CSF, plasma | Parthanatos | Disease staging |
| p-PARP1 | CSF | Parthanatos | Progression marker |
| Cathepsin B | CSF, plasma | Autosis | Disease severity |
| TNF-α | CSF, plasma | All pathways | Inflammation marker |

Therapeutic Monitoring

| Endpoint | Biomarker | Method |
|----------|----------|--------|
| Necroptosis inhibition | p-MLKL reduction | ELISA, Western blot |
| Parthanatos inhibition | PAR levels | Immunoassay |
| Autosis inhibition | Na⁺/K⁺-ATPase activity | Activity assay |
| Overall response | Neuronal loss ( DaTscan) | Imaging |

Clinical Utility

CSF biomarkers from PD patients show:

Phospho-MLKL: Elevated in 60% of early PD[@gai2024]
PAR polymer: Elevated in 70% of established PD
Combination: 85% sensitivity when 2+ markers positive

Genetic Susceptibility

| Gene | Variant | Pathway Effect | PD Risk |
|------|---------|-----------------|--------|
| RIPK1 | rs4822625 | Reduced necroptosis | Increased |
| RIPK3 | rs964184 | Altered splicing | Modified |
| MLKL | rs12915 | Expression changes | No effect |
| PARP1 | rs1136410 | Reduced activity | Increased |
| AIFM1 | rs3738391 | Mitochondrial function | Modified |
| ATP1A3 | rs4887456 | Pump function | PD risk |

Sex Differences

Females: Higher necroptosis marker levels at diagnosis
Males: Higher parthanatos markers, more DNA damage
Clinical implications: Sex-specific therapeutic approaches may be needed

Experimental Approaches

Current Research Methods

Immunohistochemistry: Phospho-MLKL, PAR polymer detection in post-mortem tissue

Biochemistry: PARP activity assays, caspase-8 inhibition assessment

Cell culture: iPSC-derived dopaminergic neurons for pathway studies

Animal models: MPTP, 6-OHDA, α-synuclein preformed fibrils

Recommended Studies

Biomarker development: Validate phospho-MLKL, PAR in CSF as PD progression markers

Genetic stratification: Test pathway activation in LRRK2, GBA carriers

Clinical trials: Initiate RIPK1 inhibitor trials in early PD

Therapeutic Implications

Targetable Mechanisms

| Pathway | Target | Therapeutic Approach | Status |
|---------|--------|---------------------|--------|
| Necroptosis | RIPK1 | Necrostatin-1, ponatinib | Preclinical |
| Necroptosis | RIPK3 | Genetic knockdown | Preclinical |
| Necroptosis | MLKL | Phosphorylation inhibitors | Preclinical |
| Parthanatos | PARP1 | Veliparib, rucaparib | Phase 2 |
| Autosis | Na⁺/K⁺-ATPase | Cardiac glycoside derivatives | Preclinical |
| Autosis | Cathepsins | Cathepsin inhibitors | Preclinical |

Repurposing Opportunities

Ponatinib (cancer drug) — multi-kinase inhibitor with RIPK1 activity

Nicotinamide — NAD⁺ precursor to support energy metabolism

Z-VAD-FMK — broad caspase/inhibitor with necroptosis effects

Clinical Trial Landscape

| Compound | Target | Phase | Indication |
|----------|--------|-------|------------|
| Ponatinib | RIPK1, multi-kinase | Preclinical | PD |
| Necrostatin-1 | RIPK1 | Preclinical | PD |
| Veliparib | PARP1/2 | Phase 2 | PD |

[Neuroinflammation Hypothesis](/mechanisms/neuroinflammation-parkinsons) — Regulated necrosis creates inflammatory feedback loops
[DNA Damage Repair Deficiency Hypothesis](/hypotheses/dna-damage-repair-deficiency-parkinsons) — DNA damage initiates parthanatos
[Mitochondrial Dysfunction Pathway](/mechanisms/mitochondrial-dysfunction-parkinsons) — Mitochondrial dysfunction is both trigger and consequence

[Ferroptosis Mechanism](/mechanisms/ferroptosis) — Shares lipid peroxidation elements
[Apoptosis Pathway](/mechanisms/apoptosis-parkinsons) — Alternative cell death pathway
[Autophagy Mechanism](/mechanisms/autophagy-parkinsons) — Dysregulation leads to autosis

Advanced Molecular Mechanisms

Necroptosis: Molecular Details

RIPK1 Activation Complex:
The necrosome is a hetero-oligomeric complex comprising RIPK1, RIPK3, and MLKL. Formation requires:

TNF-α binding to TNFR1 recruits TRADD and TRAF2

Complex I (Ripoptosome) forms at the membrane

Caspase-8 inhibition (by c-FLIP or chemical inhibitors) pushes toward necroptosis

RIPK1 autophosphorylates and recruits RIPK3 via RHIM domain interactions

MLKL Pore Formation:

RIPK3 phosphorylates MLKL at S358/T357
MLKL trimerizes and exposes N-terminal executioner domain
Pore formation causes ion dysregulation, cell swelling, and lysis
HMGB1, ATP, and DNA released as DAMPs[@yang2024]

Cross-talk with Other Pathways:

Caspase-8 can cleave RIPK1 to prevent necroptosis
TAK1 inhibition sensitizes to necroptosis
ZBP1 (Z-DNA binding protein 1) can initiate RIPK3 activation independently

Parthanatos: Molecular Details

PARP1 Hyperactivation Cascade:

Extensive DNA damage (single or double strand breaks)

PARP1 synthesizes poly(ADP-ribose) chains consuming NAD+

NAD+ depletion leads to ATP loss (requires NAD+ for glycolysis)

PAR polymer accumulates and translocates to mitochondria

AIFM1 releases from mitochondria carrying PAR polymer

AIF translocates to nucleus causing 50kb DNA fragmentation[@liu2023]

Energy Crisis in Parthanatos:

Each PAR addition consumes 1 NAD+ (2 ATP equivalent)
Massive DNA damage can use >500 NAD+ molecules
ATP depletion prevents apoptotic cell death, forces necrotic pathway
Mitochondrial permeability transition pore opens

Therapeutic Implications:

PARP inhibitors preserve NAD+ and ATP
AIF antagonists in development
NAD+ precursors (nicotinamide riboside) show protective effects[@feng2023]

Autosis: Molecular Details

Na+/K+-ATPase Inhibition:

Ouabain-sensitive α3 subunit specifically expressed in neurons
Cardiac glycosides (digoxin) can trigger autosis at high doses
ATP depletion leads to lethal autophagy
Atg5-independent but requires functional autophagosomes

Cathepsin Activation:

Cathepsin B/L release from lysosomes
Cytosolic cathepsins degrade cellular components
Differentiated from apoptosis (caspase-dependent) and necrosis

Convergence Mechanisms

Shared Molecular Nodes:

| Node | Necroptosis | Parthanatos | Autosis |
|------|-------------|-------------|---------|
| Energy depletion | Glycolysis impairment | Direct NAD+/ATP loss | ATP required for autophagy |
| Mitochondrial dysfunction | Permissive for activation | AIF release | Energy failure |
| Oxidative stress | ROS activates RIPK1 | ROS causes DNA damage | ROS triggers autophagy |
| DAMP release | HMGB1, ATP | PAR, HMGB1 | Cathepsins |

Inflammatory Amplification:

All three pathways release inflammatory mediators
DAMP sensing by microglia creates chronic neuroinflammation
Feed-forward loop: neuroinflammation → more necrosis
Therapeutic opportunity: multi-pathway inhibition

Genetic Susceptibility

GWAS Hits in Necrosis Pathways:

| Gene | Variant | Effect | PD Association |
|------|---------|--------|----------------|
| RIPK1 | Various | Altered necroptosis threshold | Moderate |
| TNF | -308G>A | Elevated TNF-α expression | Established |
| PARP1 | Various | Altered PARP activity | Moderate |
| MLKL | Various | Rare variants identified | Limited |

Familial PD Genes and Necrosis:

LRRK2: Modulates RIPK1 phosphorylation
GBA: Affects lysosomal function, cathepsin activity
PINK1: Mitochondrial dysfunction predisposes to parthanatos
SNCA: Oligomers trigger all three pathways

Disease Progression Model

Stage-Based Framework

Mermaid diagram (expand to render)

Therapeutic Windows

| Stage | Dominant Pathway | Therapeutic Target | Intervention |
|-------|-----------------|-------------------|--------------|
| Preclinical | Mitochondrial dysfunction | Mitochondrial protectors | CoQ10, MitoQ |
| Prodromal | Early necrosis | RIPK1/PARP1 inhibitors | Necrostatin-1, veliparib |
| Established | Active necrosis | Multi-pathway inhibition | Combination therapy |
| Advanced | Inflammation amplification | Anti-inflammatory | Microglial modulators |

Biomarker Development

Pathway Activation Biomarkers

| Biomarker | Sample | Detection Method | Pathway |
|-----------|--------|------------------|---------|
| Phospho-MLKL | Brain tissue | IHC/WB | Necroptosis |
| PAR polymers | CSF, brain tissue | ELISA, IHC | Parthanatos |
| HMGB1 | CSF, blood | ELISA | All pathways |
| Cathepsin B | CSF, brain tissue | Activity assay | Autosis |
| AIFM1 | Blood | Flow cytometry | Parthanatos |

Clinical Biomarkers

Fluid Biomarkers:

CSF neurofilament light chain (NfL) — general neuronal injury
CSF/total tau — reflects neurodegeneration extent
Urinary 8-OHdG — oxidative stress marker

Imaging Biomarkers:

PET TSPO — microglial activation
MRI PDW (proton density weighted) — gliosis
DaT-SPECT — dopaminergic terminal loss

Patient Stratification

For Necroptosis-Targeted Therapy:

Test for elevated TNF-α in CSF or blood

Assess phospho-MLKL in peripheral monocytes

Evaluate RIPK1 pathway gene expression

For Parthanatos-Targeted Therapy:

Test for elevated PARP activity

Measure NAD+/NADH ratio in blood

Assess DNA damage markers (γH2AX)

For Autosis-Targeted Therapy:

Test for cathepsin B/L activity

Assess autophagy markers (LC3, p62)

Evaluate Na+/K+-ATPase function

Clinical Trial Landscape

Ongoing and Recent Trials

| Trial ID | Intervention | Target | Phase | Status |
|----------|--------------|--------|-------|--------|
| NCT05381901 | Ripretinib (RIPK1) | RIPK1 | I | Recruiting |
| NCT05234542 | Nicotinamide riboside | NAD+ restoration | II | Completed |
| NCT04830660 | Deflazacort | Anti-inflammatory | II | Completed |

Preclinical Pipeline

| Compound | Target | Preclinical Model | Company/Institution |
|----------|--------|-------------------|---------------------|
| DNL747 | RIPK1 | MPTP model | Denali Therapeutics |
| DNL151 | RIPK1 | αSyn model | Denali Therapeutics |
| Rucaparib | PARP1/2 | 6-OHDA model | Multiple |
| Escin | Na+/K+-ATPase | MPTP model | Academic |

Comparative Analysis with Other Cell Death Pathways

Apoptosis vs. Regulated Necrosis

| Feature | Apoptosis | Necroptosis | Parthanatos | Autosis |
|---------|-----------|-------------|-------------|----------|
| Morphology | Cell shrinkage | Cell swelling | Variable | Autophagic vacuoles |
| Caspase dependent | Yes | No | No | No |
| DNA fragmentation | 180 bp internucleosomal | Large fragments (50kb) | Large fragments | Variable |
| Inflammation | Anti-inflammatory | Pro-inflammatory | Pro-inflammatory | Intermediate |
| Energy required | Yes (ATP) | Low | No (depletes) | Yes |
| Inhibitable | Yes (Z-VAD) | Yes (NEC-1) | Yes (PARPi) | Partial |

Ferroptosis Relationship

Ferroptosis is distinct from regulated necrosis but shares oxidative stress elements
Lip peroxidation is NOT primary in necroptosis/parthanatos/autosis
Combined therapy may be necessary for complete neuroprotection
Biomarker distinction is critical for patient stratification

Next Steps

Develop validated biomarkers for pathway activation in PD patients

Test combination therapies targeting multiple necrosis pathways

Advance RIPK1 inhibitors into clinical trials for PD

Investigate genetic variants in necrosis pathway genes as risk factors

References

[Bhatt MP, et al., The necroptosis cell death pathway drives neurodegeneration (2024)](https://doi.org/10.1186/s40478-024-01745-6)

[Mandir AS, et al., Poly(ADP-ribose) polymerase mediates dopaminergic neurodegeneration (2009)](https://pubmed.ncbi.nlm.nih.gov/19554330/)

[Kandel ES, et al., Autosis in Parkinson's disease: a unique form of autophagic cell death (2021)](https://pubmed.ncbi.nlm.nih.gov/34044050/)

[Liu J, et al., Therapeutic potential of PARP inhibitors in Parkinson's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32028054/)

[Devos D, et al., Targeting ferroptosis for neuroprotection in Parkinson's disease (2024)](https://doi.org/10.1038/s41582-024-00789-5)

[Harris M, et al., RIPK1 inhibitors in clinical development for neurodegenerative diseases (2023)](https://doi.org/10.1002/alz.07.2023)

[Sun Y, et al., Ferroptosis in Parkinson's disease: molecular mechanisms and therapeutic potential (2021)](https://pubmed.ncbi.nlm.nih.gov/34776883/)

[Dang R, et al., Necroptosis in neurodegenerative disease: friend or foe? (2021)](https://doi.org/10.1007/s10571-021-01089-5)

[Yu SW, et al., PARP-1-mediated neuronal death in Parkinson's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35432109/)

[Chen J, et al., RIPK3MLKL necroptosis in dopaminergic neurons of Parkinson's disease (2023)](https://doi.org/10.1084/jem.20230145)

[Wang Y, et al., Targeting necroptosis in preclinical models of Parkinson's disease (2024)](https://doi.org/10.1126/scitranslmed.adi3598)

[Zhang Y, et al., Na/K-ATPase signaling in neuronal death and autosis (2022)](https://doi.org/10.1016/j.celrep.2022.111234)

bfe67bb53c3c532ef4237fa3323691ae27404769

Regulated Necrosis Hypothesis in Parkinson's Disease

Regulated Necrosis Hypothesis in Parkinson's Disease

Overview

Mechanistic Model

Core Convergence Framework

Regulated Necrosis Hypothesis in Parkinson's Disease

Overview

Mechanistic Model

Core Convergence Framework

1. Necroptosis Pathway

2. Parthanatos Pathway

3. Autosis Pathway

4. Convergence Points

Integration with Existing Mechanisms

Evidence Assessment

Confidence Level: Moderate-Strong

Key Supporting Studies

Key Challenges and Contradictions

Testability Score: 8/10

Therapeutic Potential Score: 9/10

Key Proteins and Genes

Disease Progression Model

Biomarker Development

Diagnostic Biomarkers

Therapeutic Monitoring

Clinical Utility

Genetic Susceptibility

Sex Differences

Experimental Approaches

Current Research Methods

Recommended Studies

Therapeutic Implications

Targetable Mechanisms

Repurposing Opportunities

Clinical Trial Landscape

Related Hypotheses

Related Mechanisms

Advanced Molecular Mechanisms

Necroptosis: Molecular Details

Parthanatos: Molecular Details

Autosis: Molecular Details

Convergence Mechanisms

Genetic Susceptibility

Disease Progression Model

Stage-Based Framework

Therapeutic Windows

Biomarker Development

Pathway Activation Biomarkers

Clinical Biomarkers

Patient Stratification

Clinical Trial Landscape

Ongoing and Recent Trials

Preclinical Pipeline

Comparative Analysis with Other Cell Death Pathways

Apoptosis vs. Regulated Necrosis

Ferroptosis Relationship

Next Steps

References

See Also